Physician profile
Brian Wasserman
NPI 1730188905
$75,018.94
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $15K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $56,530.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $17,537.89 | 2019-2020 | |
| Amgen INC. | $373.92 | 2019 | |
| Lilly USA, LLC | $324.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.49 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.59 | 2019 | |
| Insulet Corporation | $29.98 | 2019 | |
| Radius Health, INC. | $18.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.93 | 2020 | |
| Merck Sharp & Dohme LLC | $12.24 | 2019 | |
| Lifescan, INC. | $11.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.